secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mineralys Therapeutics, Inc. (MLYS)
CIK:        0001933414
Form:       8-K
Filed at:   2025-02-12T23:59:59+00:00
Accession:  0001933414-25-000008
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mineralys reports FY2024 net loss $177.8M; cash $198.2M; pivotal data expected Q1-Q2 2025
--------------------------------------------------------------------------------

- Net loss for FY2024 was $177.8M vs $71.9M in FY2023; R&D spend $168.6M vs $70.4M.
- Cash, equivalents and investments $198.2M as of Dec 31, 2024; expected to fund operations through Q1 2026.
- Topline data from pivotal Advance-HTN trial expected March 2025; Launch-HTN Phase 3 data in mid first half 2025.
- Enrollment in Explore-CKD Phase 2 complete; topline data anticipated Q2 2025.
- Initiating Phase 2 trial for lorundrostat in moderate-to-severe OSA and hypertension in Q1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1933414/000193341425000008/0001933414-25-000008-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1933414/000193341425000008/mlys-20250212.htm
  HTML page:      https://secwatch.observer/filing/0001933414-25-000008

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer